We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stem Cell Differentiation Depends on the Central Metabolic Regulator AMPK

By LabMedica International staff writers
Posted on 11 May 2016
The ability of stem cells to differentiate into mature tissue depends on the activity of the central metabolic regulator AMP-activated protein kinase (AMPK).

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) reported in the March 2016 issue of the journal Genes & Development that although AMPK-deficient embryonic stem cells (ESCs) were normal in the pluripotent state, these cells displayed profound defects upon differentiation, failing to generate chimeric embryos and preferentially adopting an ectodermal fate at the expense of the endoderm during embryoid body (EB) formation.

EBs lacking AMPK exhibited reduced levels of Tfeb (Transcription factor EB), a master transcriptional regulator of lysosomes, which led to diminished endolysosomal function. More...
Reintroduction of Tfeb into the dysfunctional cells restored normal development and differentiation.

"Even though there is great interest in AMPK related to diabetes and cancer, frankly nothing was known about how this fuel gauge process changes in different cell populations during development," said senior author Dr. Reuben Shaw, professor of molecular and cell biology at the Salk Institute for Biological Studies. "It was thought that lysosomes and AMPK were connected somehow, but no one had dreamed that you would get no lysosomes if you do not have this fuel gauge. Connecting the AMPK pathway to lysosomes begs the question of whether this pathway is part of anticancer pathways as well. We are decoding some of these underlying connections that might indicate when and how a cancer drugs might be useful. This work may also help up make better, more specific ways of targeting lysosomes in cancer."

Related Links:
Salk Institute for Biological Studies


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.